Is DVA a good investment?
DaVita (DVA) currently holds a consensus "Hold" rating among analysts. While 33% of analysts recommend a "Strong Buy," 50% suggest "Holding," and 17% advise "Selling." The company is the largest dialysis provider in the United States, which gives it a stable, albeit challenged, market position. Bulls point to its dominance in the dialysis sector and the strategic investment from Berkshire Hathaway as signs of long-term stability. Bears, however, emphasize significant risks, particularly its heavy reliance on Medicare reimbursement rates, which account for about two-thirds of its U.S. sales, and slowing organic volume trends. Because of this reliance on government payers and the pressure on profit margins, the investment is currently viewed with cautious neutrality by the majority of the professional analyst community.
Related FAQs
Yes, "Dx" is a standard medical abbreviation used by healthcare professionals as shorthand for "diagnosis.
Warren Buffett does not hold shares of Diageo plc (trading under the ticker DEO) within Berkshire Hathaway's investment portfolio.
The Chief Executive Officer of Dollar Tree Inc. is compensated through a structured executive remuneration plan outlined in annual proxy filings. Total annual compensation for the chief executive officer typically ranges between 7.6 million and 9.
As of mid-2026, analyst consensus on DaVita (DVA) is mixed and suggests a cautious approach. Recent ratings indicate that 33% of analysts recommend a "Strong Buy," while 50% suggest "Holding" the stock, and 17% advise "Selling".
DaVita has undergone several rounds of layoffs and job cuts over the past few years, particularly between 2022 and 2024, as part of a multi-year restructuring and cost-cutting initiative.
As of July 2026, there is significant debate regarding the valuation of DaVita (DVA) stock.